Table 3.
Compliance with EULAR/ACR 2019 Criteria in the population studied.
| Criteria |
N (%) |
|---|---|
| N Total |
146 (100) |
| EULAR/ACR 2019 | 124 (84.93) |
| Fever | 8/140 (5.71) |
| Mucocutaneous | 67 (45.9) |
| Hematological | 84 (57.5) |
| Thrombocytopenia | 39/136 (28.68) |
| Autoimmune hemolysis | 37/142 (26.06) |
| Leukopenia | 35/138 (25.3) |
| Neuropsychiatric | 16 (10.9) |
| Seizures | 9/141 (6.38) |
| Psychosis | 6/142 (4.23) |
| Delirium | 4/141 (2.84) |
| Mucocutaneous | 67 (45.9) |
| Non-scarring alopecia | 40/137 (29.2) |
| Oral ulcers | 32/135 (23.7) |
| Subacute cutaneous lupus or discoid lupus | 12/146 (8.2) |
| Acute cutaneous lupus | 7/131 (5.34) |
| Serosal | 31 (21.2) |
| Acute pericarditis | 6/141 (4.26) |
| Pleural effusion or pericardial effusion | 31/140 (22.14) |
| Musculoskeletal | 93 (63.7) |
| Renal | 56 (38.35) |
| Proteinuria > 0.5 g/24h | 49/140 (35) |
| Renal biopsy Class III or IV kidney | 22/128 (17.19%) |
| Renal biopsy Class II or V kidney | 17/129 (13.18%) |
| Immunological domains and criteria | |
| Antiphospholipid antibodies | 45/146 (30.8) |
| LA | 30/101 (20.5%) |
| IGG aCL | 16/103 (15.53%) |
| IGM aCL | 16/100 (16.0%) |
| IGA aCL | 6/46 (13.04%) |
| IGM B2GPI | 11/83 (13.25%) |
| IGG B2GPI | 10/83 (12.05%) |
| IGA B2GPI | 3/41 (7.32%) |
| Complement | 99 (67.8) |
| Low C3 OR low C4 | 26/146 (17.81) |
| Low C3 AND low C4 | 73/146 (50.0) |
| SLE-specific antibodies | 91 (62.3) |
| Anti dsDNA | 74/131(56.49%) |
| AntiSM | 47/119 (39.50%) |
ACR 2019.2019 Classification of the European League Against Rheumatism and the American College of Rheumatology for the diagnosis of systemic lupus erythematosus, ANA: Antinuclear antibody, anti-dsDNA: anti-double-stranded deoxyribonucleic acid, anti-SM: anti-Smith, aCL. Anti-Cardiolipin, B2GPI: anti-β2-glycoprotein I, CH50: total complement activity, LA: Lupus anticoagulant.